Search results for " glucose-dependent insulinotropic polypeptide"

showing 4 items of 4 documents

Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis.

2015

Aims/Introduction According to some authors, in type 2 diabetes there is a reduced postprandial action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, little is known about the role of fasting incretins in glucose homeostasis. Our aim was to evaluate, through a two-step cluster analysis, the possibility of phenotyping patients with type 2 diabetes at onset on the basis of fasting GLP-1, GIP and ghrelin. Materials and Methods A total of 96 patients with type 2 diabetes within 6 months of onset (mean age 62.40 ± 6.36 years) were cross-sectionally studied. Clinical, anthropometric and metabolic parameters were evaluated. At fasting the follow…

Blood GlucoseMalemedicine.medical_treatmentEndocrinology Diabetes and MetabolismSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineGlucagon-Like Peptide 1Glucose homeostasisCluster AnalysisHomeostasis030212 general & internal medicineGeneral MedicineArticlesMiddle AgedGlucagon-like peptide-1GhrelinGlucagon‐like peptide‐1PhenotypeClinical Science and CareFemaleOriginal Articlehormones hormone substitutes and hormone antagonistsGlucagon-like peptide-1medicine.medical_specialtyGlucose-dependent insulinotropic polypeptideIncretin030209 endocrinology & metabolismGastric Inhibitory PolypeptideGhrelin; Glucagon-like peptide-1; Glucose-dependent insulinotropic polypeptide; Endocrinology Diabetes and Metabolism; Internal MedicineIncretins03 medical and health sciencesInsulin resistanceGlucose‐dependent insulinotropic polypeptideInternal medicineDiabetes mellitusmedicineInternal MedicineHumansAgedAdiponectinbusiness.industryInsulinmedicine.diseaseEndocrinologyGlucosechemistryDiabetes Mellitus Type 2Glycated hemoglobinInsulin ResistancebusinessJournal of diabetes investigation
researchProduct

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women

2022

We showed that twenty weeks of SuperJump activity, an innovative workout training performed on an elastic minitrampoline, reduced bone resorption and increased bone formation in eumenorrheic women acting on the key points of the regulation of bone metabolism. The present study analyzed whether the gastrointestinal hormones are involved in the mechanism of action and if it has an impact on glucose homeostasis. The control group was composed of twelve women, similar to the exercise group that performed SuperJump activity for twenty weeks. The analysis was performed on blood samples and investigated GLP-1, GIP, GLP-2, PYY, ghrelin, glucose, insulin, insulin resistance, β-cell function, and ins…

Glucagon-like peptide-1endocrine systemBiological mechanismsGeneral Immunology and MicrobiologyGlucose‐dependent insulinotropic polypeptidedigestive oral and skin physiologyPhysical healthbiological mechanisms; physical health; sports and exercise physiology; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptideGeneral Agricultural and Biological Scienceshormones hormone substitutes and hormone antagonistsGeneral Biochemistry Genetics and Molecular BiologySports and exercise physiology
researchProduct

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Trea…

2022

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease (CVD). Lifestyle, as well as an imbalance of energy intake/expenditure, genetic predisposition, and epigenetics could lead to a dysmetabolic milieu, which is the cornerstone for the development of cardiometabolic complications. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs promote positive effects on most components of the “ cardiometabolic continuum” an…

Metabolic SyndromePharmacologyglucagon-like peptide-1 receptor agonists glucose-dependent insulinotropic polypeptide receptor agonists non-alcoholic fatty liver disease obesity prediabetes tirzepatide type 2 diabetes mellitusGlucagon-Like Peptide-1 ReceptorPrediabetic StateGlucoseDiabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide 1HumansPharmacology (medical)ObesityPeptidesCardiology and Cardiovascular MedicineJournal of Cardiovascular Pharmacology and Therapeutics
researchProduct

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction

2022

The incretin pathway is a self-regulating feedback system connecting the gut with the brain, pancreas, and liver. Its predominant action is on the postprandial glucose levels, with extraglycemic effects on fat metabolism and endovascular function. Of the two main incretin hormones released with food ingestion, the actions of glucagon-like peptide-1 (GLP-1) have been exploited for therapeutic benefit. However, little attention has been paid to glucose-dependent insulinotropic polypeptide (GIP) until the recent experimental introduction of dual agonists, or "twincretins". Interestingly, simultaneous activation of both receptors is not only replicative of normal physiology, it seems to be an i…

PharmacologyInternal Medicineglucagon-like peptide-1 glucose-dependent insulinotropic polypeptide incretins type 2 diabetesDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
researchProduct